)

Zentalis Pharmaceuticals (ZNTL) investor relations material
Zentalis Pharmaceuticals Morgan Stanley 23rd Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic focus and clinical development
Lead asset azenosertib is being advanced in platinum-resistant ovarian cancer, targeting patients with cyclin E1 protein overexpression.
The Denali trial is a registration-intent study aiming for accelerated approval, with a phase 3 confirmatory trial planned.
A clear strategic focus was established to prioritize azenosertib in ovarian cancer, with capital allocated to this path and ongoing trials in other indications.
The company underwent restructuring to ensure sufficient capital, reporting $303 million in cash and equivalents, providing runway into late 2027.
Clinical data and trial design
Integrated analysis across multiple studies showed consistent response rates and durability for azenosertib, with a 35% response rate and 6.3 months duration in Denali part 1.
The selected dosing regimen is 400 mg, five days on, two days off, based on efficacy and tolerability.
Cyclin E1 biomarker enrichment improved response rates by over 10%, and prospective enrichment is being used in Denali part 2.
Denali part 2A is a randomized dose confirmation (300 mg vs 400 mg), with part 2B expanding to a registrational size; top-line data expected end of 2026.
The FDA has aligned with the trial design, including the need for a confirmatory phase 3 trial in the same patient population.
Safety, regulatory, and market positioning
Safety profile is considered manageable, with protocol updates and site management to address adverse events.
A brief clinical hold was resolved without changes to dose or schedule, and the FDA expressed confidence in the program.
The target market is about 21,500 patients annually in the US, representing 50% of the platinum-resistant ovarian cancer population.
Expansion opportunities include earlier lines of ovarian cancer, combinations with other agents, and other tumor types such as HER2-positive and triple-negative breast cancer.
The company remains focused on its lead indication but is open to further development if additional capital becomes available.
Next Zentalis Pharmaceuticals earnings date

Next Zentalis Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage